Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 1Breast 1

Conditions

Breast Neoplasms 23Triple Negative Breast Neoplasms 14Ovarian Neoplasms 9Fallopian Tube Neoplasms 4Stomach Neoplasms 3Lung Neoplasms 3Colonic Neoplasms 3Breast Neoplasms, Male 3Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Melanoma 2Hereditary Breast and Ovarian Cancer Syndrome 2Testicular Neoplasms 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Neoplasms, Unknown Primary 1Liver Failure 1Hemangiosarcoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

Early Intervention, Educational 5Radiotherapy 4Psychiatric Rehabilitation 4Capecitabine 4pembrolizumab 3Trastuzumab 3Methods 3Magnetic Resonance Spectroscopy 3Irinotecan 3Gemcitabine 3Counseling 3trametinib 2palbociclib 2cediranib 2Standard of Care 2Mental Status and Dementia Tests 2Fluorodeoxyglucose F18 2Docetaxel 2Cyclophosphamide 2Biopsy 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 2veliparib 1ulixertinib 1trastuzumab biosimilar HLX02 1tipifarnib 1spartalizumab 1sargramostim 1sapanisertib 1relatlimab 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × veliparib × Breast × Clear all
NCT01233505 2014-04-02

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Terminated
16 enrolled
BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡